This report attempts to group the 2,455 participants that ever ever consented to the Northwestern ADRC into groups by their baseline clinical diagnosis, their clinical diagnosis at their last visit, and their pathologic diagnosis after death.
Summary of the clinical diagnosis at every participant’s last visit
Total | Pre-UDS3 | UDS3 | ||
|---|---|---|---|---|
Total | 2,455 | 1,920 | 535 | |
AD | 452 | 381 | 71 | |
MCI | 314 | 273 | 41 | |
Impaired Not MCI | 0 | 0 | 0 | |
NC | 663 | 442 | 221 | |
PPA | 386 | 264 | 122 | |
FTD | 84 | 42 | 42 | |
Other | 548 | 516 | 32 | |
Summary of the clinical diagnosis at every participant’s first visit in which a clinical diagnosis was assessed by the diagnosis at their last visit.
AD at Final | MCI at Final | NC at Final | PPA at Final | FTD at Final | Other at Final | Unknown at Final | ||
|---|---|---|---|---|---|---|---|---|
Total | 452 | 314 | 663 | 386 | 84 | 548 | 8 | |
AD at Baseline | 230 | 1 | 0 | 3 | 2 | 28 | 1 | |
MCI at Baseline | 39 | 80 | 16 | 10 | 3 | 13 | 1 | |
Impaired Not MCI at Baseline | 1 | 1 | 2 | 0 | 0 | 3 | 0 | |
NC at Baseline | 22 | 46 | 431 | 0 | 0 | 17 | 3 | |
PPA at Baseline | 0 | 0 | 0 | 285 | 0 | 6 | 0 | |
FTD at Baseline | 4 | 0 | 0 | 3 | 74 | 70 | 1 | |
Other at Baseline | 3 | 1 | 0 | 2 | 4 | 59 | 0 | |
Unknown at Baseline | 153 | 185 | 214 | 83 | 1 | 352 | 2 | |
Summary of deceased and autopsy status by pathological diagnosis
Total | Pre-UDS3 | UDS3 | ||||
|---|---|---|---|---|---|---|
Total | 2,455 | 1,920 | 535 | |||
Deceased | 971 | 845 | 126 | |||
Autopsy Completed | 678 | 598 | 80 | |||
AD | 489 | 435 | 54 | |||
FTD | 127 | 114 | 13 | |||
NC | 11 | 9 | 2 | |||
Other | 39 | 36 | 3 | |||
Unknown | 12 | 4 | 8 | |||
Autopsy Not Expected | 293 | 247 | 46 | |||
Unknown | 293 | 247 | 46 | |||
Not Deceased | 1,479 | 1,070 | 409 | |||
First visit in witch a clinical diagnosis was assessed. For example, if the participant participated in 10 research visits, but their was no clinical diagnosis associated to the first 5, that participant’s first visit with a clinical diagnosis would be visit 6.
Total | Pre-UDS3 | UDS3 | ||
|---|---|---|---|---|
Total | 2,455 | 1,906 | 549 | |
AD | 265 | 202 | 63 | |
MCI | 162 | 101 | 61 | |
Impaired Not MCI | 7 | 5 | 2 | |
NC | 519 | 283 | 236 | |
PPA | 291 | 173 | 118 | |
FTD | 152 | 112 | 40 | |
Other | 69 | 46 | 23 | |
Unknown | 990 | 984 | 6 | |
Clinical diagnosis at every participant’s first visit.
Total | Pre-UDS3 | UDS3 | ||
|---|---|---|---|---|
Total | 2,455 | 1,920 | 535 | |
AD | 213 | 153 | 60 | |
MCI | 120 | 61 | 59 | |
Impaired Not MCI | 5 | 3 | 2 | |
NC | 338 | 108 | 230 | |
PPA | 274 | 156 | 118 | |
FTD | 140 | 100 | 40 | |
Other | 57 | 37 | 20 | |
Unknown | 1,308 | 1,302 | 6 | |
Clinical diagnosis for every participant at every research visit.
Total | Pre-UDS3 | UDS3 | ||
|---|---|---|---|---|
Total | 12,834 | 8,592 | 4,242 | |
AD | 1,291 | 696 | 595 | |
MCI | 640 | 298 | 342 | |
Impaired Not MCI | 63 | 29 | 34 | |
NC | 3,223 | 1,257 | 1,966 | |
PPA | 1,457 | 567 | 890 | |
FTD | 528 | 283 | 245 | |
Other | 289 | 144 | 145 | |
Unknown | 5,343 | 5,318 | 25 | |